Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
Publication|Articles|June 21, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Outcomes of Older Patients on Enfortumab Vedotin for Urothelial Carcinoma
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
The treatment landscape for advanced urothelial carcinoma (aUC) has undergone a significant transformation since the FDA approval of enfortumab vedotin (EV) in 2019. Although results from pivotal trials have been practice-changing, older adults were underrepresented in these studies, and data including these patients remain limited. This study compares efficacy and safety outcomes between patients aged 70 or older and those younger than 70 years receiving EV therapy, using real-world data.
Related to this article
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Advertisement
Advertisement